Anil Kumar, Srividya Swaminathan*
Studies on Natural Killer (NK) cells have demonstrated their potential in treating hematological malignancies and solid tumors. Because they are potentially safer and easier to engineer than T cell-based therapies, NK cells are a particularly attractive platform for developing off-the-shelf cellular treatments. Development of allogeneic NK cellbased therapies requires a detailed understanding of how autologous NK cells are suppressed in patients with cancers.